Atomo Diagnostics (AT1) Stock Overview
Engages in the development and sale of medical devices worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
AT1 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Atomo Diagnostics Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.028 |
| 52 Week High | AU$0.032 |
| 52 Week Low | AU$0.014 |
| Beta | 1.08 |
| 1 Month Change | 0% |
| 3 Month Change | 40.00% |
| 1 Year Change | 40.00% |
| 3 Year Change | -50.88% |
| 5 Year Change | -91.38% |
| Change since IPO | -92.82% |
Recent News & Updates
Recent updates
We Think Atomo Diagnostics (ASX:AT1) Can Afford To Drive Business Growth
Jul 05
We Think Atomo Diagnostics (ASX:AT1) Can Afford To Drive Business Growth
Oct 10Is Atomo Diagnostics (ASX:AT1) In A Good Position To Invest In Growth?
Jun 10We're Not Worried About Atomo Diagnostics' (ASX:AT1) Cash Burn
Dec 06Atomo Diagnostics Limited (ASX:AT1) Shares Could Be 50% Below Their Intrinsic Value Estimate
Nov 01We're Interested To See How Atomo Diagnostics (ASX:AT1) Uses Its Cash Hoard To Grow
Jul 19Market Sentiment Around Loss-Making Atomo Diagnostics Limited (ASX:AT1)
Feb 26Atomo Diagnostics (ASX:AT1) Is In A Strong Position To Grow Its Business
Jan 22Here's What Atomo Diagnostics Limited's (ASX:AT1) Shareholder Ownership Structure Looks Like
Dec 18
When Can We Expect A Profit From Atomo Diagnostics Limited (ASX:AT1)?
Jul 16Shareholder Returns
| AT1 | AU Medical Equipment | AU Market | |
|---|---|---|---|
| 7D | 12.0% | -3.1% | -2.3% |
| 1Y | 40.0% | -3.7% | 3.9% |
Return vs Industry: AT1 exceeded the Australian Medical Equipment industry which returned -3.7% over the past year.
Return vs Market: AT1 exceeded the Australian Market which returned 3.9% over the past year.
Price Volatility
| AT1 volatility | |
|---|---|
| AT1 Average Weekly Movement | 14.7% |
| Medical Equipment Industry Average Movement | 11.5% |
| Market Average Movement | 9.6% |
| 10% most volatile stocks in AU Market | 19.5% |
| 10% least volatile stocks in AU Market | 3.5% |
Stable Share Price: AT1's share price has been volatile over the past 3 months compared to the Australian market.
Volatility Over Time: AT1's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | n/a | John Kelly | atomodiagnostics.com |
Atomo Diagnostics Limited engages in the development and sale of medical devices worldwide. The company offers blood test devices, such as Pascal, Curie, Galileo, Elion, and Florey under the AtomoRapid brand. It also offers HIV Rapid self-Test device; and digital health solutions.
Atomo Diagnostics Limited Fundamentals Summary
| AT1 fundamental statistics | |
|---|---|
| Market cap | AU$22.68m |
| Earnings (TTM) | -AU$4.97m |
| Revenue (TTM) | AU$3.79m |
Is AT1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AT1 income statement (TTM) | |
|---|---|
| Revenue | AU$3.79m |
| Cost of Revenue | AU$2.00m |
| Gross Profit | AU$1.79m |
| Other Expenses | AU$6.76m |
| Earnings | -AU$4.97m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0061 |
| Gross Margin | 47.28% |
| Net Profit Margin | -131.08% |
| Debt/Equity Ratio | 0% |
How did AT1 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/18 16:50 |
| End of Day Share Price | 2025/11/18 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Atomo Diagnostics Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Martyn Jacobs | Canaccord Genuity |